文献速递淋巴瘤白血病

化学免疫治疗后奥妥珠单抗巩固治疗:英国国家癌症研究所GALACTIC II/III期试验结果

Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
PubMed 文献 · Br J Haematol · 2022-08-26

GALACTIC是一项无缝II/III期试验,评估奥妥珠单抗巩固治疗能否安全清除微小残留病(MRD)并延长无进展生存期(PFS)。因招募缓慢,试验在II期后关闭。29例MRD阳性患者中14例接受巩固、15例不接受;随机化后6个月,巩固组分别有10例和13例在骨髓和外周血达到流式细胞术MRD阴性(灵敏度10⁻⁴)。巩固组PFS显著优于非巩固组(p=0.001)。

要点

  • 29例MRD阳性CLL患者随机分为奥妥珠单抗巩固组14例与无巩固组15例。
  • 随机化后6个月,巩固组骨髓和外周血分别有10例和13例达到流式细胞术MRD阴性(灵敏度10⁻⁴)。
  • 巩固组PFS显著优于非巩固组(p=0.001),巩固组常见不良事件为血小板减少、感染和咳嗽。

核心结论

  • 该观察进一步证明,通过巩固治疗达到MRD阴性可改善CLL患者的结局,且奥妥珠单抗在低疾病负荷患者中耐受良好。

研究设计与样本

  • GALACTIC是一项无缝II/III期试验,旨在检验奥妥珠单抗巩固治疗是否安全、能否清除MRD,以及能否延长近期对化学免疫治疗有反应的CLL患者的PFS。
  • 对化学免疫治疗后3-24个月有反应的患者评估MRD,MRD阳性患者随机接受奥妥珠单抗巩固治疗或不接受巩固治疗。
  • 因招募缓慢,试验在II期部分后关闭;共入组48例患者,其中19例MRD阴性者接受监测。
  • 29例MRD阳性患者中,14例随机接受巩固治疗,15例不接受巩固治疗。

主要发现

  • 随机化后6个月,巩固组分别有10例和13例在骨髓和外周血达到流式细胞术MRD阴性(灵敏度10⁻⁴)。
  • 巩固组PFS显著优于非巩固组(p=0.001)。
  • 比较巩固后10例MRD阴性患者与监测组19例MRD阴性患者,PFS、总生存或MRD阴性持续时间均无差异。
  • 巩固组常见不良事件为血小板减少、感染和咳嗽,仅1%的事件为输注相关反应。

局限性

  • 因招募缓慢,试验在II期部分后关闭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III trial designed to test whether consolidation with obinutuzumab is safe and eradicates minimal residual disease (MRD) and, subsequently, whether this leads to prolonged progression-free survival (PFS) in patients with CLL who have recently responded to chemo-immunotherapy. Patients with a response 3-24 months after chemotherapy were assessed for MRD. MRD-positive patients were randomised to receive consolidation therapy with obinutuzumab or no consolidation. The trial closed after the phase II part due to slow recruitment. In all, 48 patients enrolled of whom 19 were MRD negative and were monitored. Of the 29 MRD-positive patients, 14 were randomised to receive consolidation and 15 to no consolidation. At 6 months after randomisation, 10 and 13 consolidated patients achieved MRD negativity by flow cytometry (sensitivity 10-4 ) in bone marrow and peripheral blood respectively. PFS was significantly better in consolidated patients compared to non-consolidated patients (p = 0.001). No difference was observed in PFS, overall survival or duration of MRD negativity when comparing the 10 MRD-negative patients after consolidation with the 19 MRD-negative patients in the monitoring group. Common adverse events in the consolidation arm were thrombocytopenia, infection, and cough. Only 1% of events were infusion-related reactions. This observation provides further evidence that consolidation to achieve MRD negativity improves outcomes in CLL and that obinutuzumab is well tolerated in patients with low levels of disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Munir T, Emmerson J, Hockaday A, et al. Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. Br J Haematol. 2022. PMID: 36017875. doi:10.1111/bjh.18427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。